A. Chemaissani

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

Rafael Rosell, U. Gatzemeier, Daniel Betticher et al. · Annals of Oncology · 2002 · 298 citations · Full text

Medicine, Phase Iii, Clinical Trials +9

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer

Rafael Rosell, G. Robinet, A. Szczęsna et al. · Annals of Oncology · 2007 · 260 citations · Full text

First-line Therapy, Non-small-cell Lung Cancer, Medicine +9

Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer

C. Manegold, Bengt Bergman, A. Chemaissani et al. · Annals of Oncology · 1997 · 114 citations · Full text

Medicine, Single-agent Gemcitabine, Metronomic Therapy +7

Multicenter Randomized Trial for Stage IIIB/IV Non–Small-Cell Lung Cancer Using Every-3-Week Versus Weekly Paclitaxel/Carboplatin

Wolfgang Schuette, Thomas Blankenburg, Wolf Guschall et al. · Clinical Lung Cancer · 2006 · 46 citations

Medicine, Metronomic Therapy, Clinical Trials +8

Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy

A. A. Fauser, Bernard Duclos, A. Chemaissani et al. · European Journal of Cancer · 1996 · 39 citations

Emetogenic Chemotherapy, Medicine, Metronomic Therapy +5